

1 **Transmission potential of vaccinated and unvaccinated persons infected with the SARS-CoV-2 Delta**  
 2 **variant in a federal prison, July—August 2021**

3 **Supplementary Materials**

4  
 5 **Supplementary Table 1. Results of hypothesis tests for RT-PCR test viral culture test survival functions.**

<b>Outcome</b>	<b>Category</b>	<b>Reference Group</b>	<b>Test Statistic*</b>	<b>P-Value*</b>
RT-PCR Survival Function	Unvaccinated	Fully Vaccinated	-1.30	0.50
RT-PCR Survival Function	Pfizer	Moderna	-2.70	0.13
RT-PCR Survival Function	Pfizer	Janssen	-0.06	0.97
RT-PCR Survival Function	Moderna	Janssen	0.65	0.62
RT-PCR Survival Function	Pfizer	All Products	-2.48	0.39
RT-PCR Survival Function	Moderna	All Products	2.63	0.39
RT-PCR Survival Function	Janssen	All Products	-0.15	0.39
RT-PCR Survival Function	More than 120 Days	Less than 120 Days	-2.27	0.32
RT-PCR Survival Function	Prior Infection	No Prior Infection	1.62	0.12
Viral Culture Survival Function	Unvaccinated	Fully Vaccinated	-1.91	0.29
Viral Culture Survival Function	Pfizer	Moderna	-2.84	0.048
Viral Culture Survival Function	Pfizer	Janssen	1.60	0.12
Viral Culture Survival Function	Moderna	Janssen	3.01	0.003
Viral Culture Survival Function	More than 120 Days	Less than 120 Days	-0.64	0.79
Viral Culture Survival Function	Prior Infection	No Prior Infection	0.00	0.99

6 \*Test statistics and p-values correspond to the generalized Wilcoxon-Mann-Whitney hypothesis testing  
 7 method for interval-censored data.

8 **Supplementary Table 2 . Results of hypothesis tests for Cycle threshold value distributions.**


Category	Days Since Onset	Test Name	Test Statistic	Bonferroni $\alpha$	P-Value
Vaccination Status	0	Wilcoxon Mann-Whitney U	0.21	0.0026	0.832
Vaccination Status	1	Wilcoxon Mann-Whitney U	1.34	0.0026	0.180
Vaccination Status	2	Wilcoxon Mann-Whitney U	0.35	0.0026	0.729
Vaccination Status	3	Wilcoxon Mann-Whitney U	0.13	0.0026	0.899
Vaccination Status	4	Wilcoxon Mann-Whitney U	-0.82	0.0026	0.412
Vaccination Status	5	Wilcoxon Mann-Whitney U	0.31	0.0026	0.755
Vaccination Status	6	Wilcoxon Mann-Whitney U	1.53	0.0026	0.127
Vaccination Status	7	Wilcoxon Mann-Whitney U	1.10	0.0026	0.272
Vaccination Status	8	Wilcoxon Mann-Whitney U	0.41	0.0026	0.682
Vaccination Status	9	Wilcoxon Mann-Whitney U	1.03	0.0026	0.301
Vaccination Status	10	Wilcoxon Mann-Whitney U	0.54	0.0026	0.587
Vaccination Status	11	Wilcoxon Mann-Whitney U	-0.31	0.0026	0.756
Vaccination Status	12	Wilcoxon Mann-Whitney U	0.43	0.0026	0.665
Vaccination Status	13	Wilcoxon Mann-Whitney U	-0.89	0.0026	0.374
Vaccination Status	14	Wilcoxon Mann-Whitney U	-0.42	0.0026	0.672
Vaccination Status	15	Wilcoxon Mann-Whitney U	-1.20	0.0026	0.231
Vaccination Status	16	Wilcoxon Mann-Whitney U	-1.28	0.0026	0.200
Vaccination Status	17	Wilcoxon Mann-Whitney U	-1.70	0.0026	0.090
Vaccination Status	18	Wilcoxon Mann-Whitney U	-0.13	0.0026	0.894
Vaccine Product	0	Kruskal-Wallis	0.35	0.0026	0.839
Vaccine Product	1	Kruskal-Wallis	2.71	0.0026	0.258
Vaccine Product	2	Kruskal-Wallis	3.07	0.0026	0.215
Vaccine Product	3	Kruskal-Wallis	8.19	0.0026	0.017
Vaccine Product	4	Kruskal-Wallis	6.79	0.0026	0.034
Vaccine Product	5	Kruskal-Wallis	3.86	0.0026	0.145
Vaccine Product	6	Kruskal-Wallis	4.70	0.0026	0.095
Vaccine Product	7	Kruskal-Wallis	0.84	0.0026	0.658
Vaccine Product	8	Kruskal-Wallis	6.20	0.0026	0.045
Vaccine Product	9	Kruskal-Wallis	2.89	0.0026	0.235
Vaccine Product	10	Kruskal-Wallis	2.06	0.0026	0.356
Vaccine Product	11	Kruskal-Wallis	0.12	0.0026	0.943
Vaccine Product	12	Kruskal-Wallis	0.24	0.0026	0.889
Vaccine Product	13	Kruskal-Wallis	0.17	0.0026	0.916
Vaccine Product	14	Kruskal-Wallis	0.31	0.0026	0.855
Vaccine Product	15	Kruskal-Wallis	0.92	0.0026	0.633
Vaccine Product	16	Kruskal-Wallis	1.83	0.0026	0.400
Vaccine Product	17	Kruskal-Wallis	0.14	0.0026	0.705

<b>Vaccine Product</b>	18	Kruskal-Wallis	0.86	0.0026	0.353
<b>Time Since Vaccination</b>	0	Wilcoxon Mann-Whitney U	-1.95	0.0026	0.052
<b>Time Since Vaccination</b>	1	Wilcoxon Mann-Whitney U	-0.11	0.0026	0.916
<b>Time Since Vaccination</b>	2	Wilcoxon Mann-Whitney U	0.09	0.0026	0.929
<b>Time Since Vaccination</b>	3	Wilcoxon Mann-Whitney U	-0.69	0.0026	0.488
<b>Time Since Vaccination</b>	4	Wilcoxon Mann-Whitney U	-0.65	0.0026	0.516
<b>Time Since Vaccination</b>	5	Wilcoxon Mann-Whitney U	-1.41	0.0026	0.158
<b>Time Since Vaccination</b>	6	Wilcoxon Mann-Whitney U	-0.53	0.0026	0.595
<b>Time Since Vaccination</b>	7	Wilcoxon Mann-Whitney U	-0.32	0.0026	0.746
<b>Time Since Vaccination</b>	8	Wilcoxon Mann-Whitney U	1.14	0.0026	0.255
<b>Time Since Vaccination</b>	9	Wilcoxon Mann-Whitney U	0.43	0.0026	0.669
<b>Time Since Vaccination</b>	10	Wilcoxon Mann-Whitney U	1.56	0.0026	0.119
<b>Time Since Vaccination</b>	11	Wilcoxon Mann-Whitney U	0.31	0.0026	0.754
<b>Time Since Vaccination</b>	12	Wilcoxon Mann-Whitney U	0.32	0.0026	0.750
<b>Time Since Vaccination</b>	13	Wilcoxon Mann-Whitney U	0.40	0.0026	0.686
<b>Time Since Vaccination</b>	14	Wilcoxon Mann-Whitney U	0.66	0.0026	0.510
<b>Time Since Vaccination</b>	15	Wilcoxon Mann-Whitney U	-0.42	0.0026	0.671
<b>Time Since Vaccination</b>	16	Wilcoxon Mann-Whitney U	1.18	0.0026	0.239
<b>Time Since Vaccination</b>	17	Wilcoxon Mann-Whitney U	0.67	0.0026	0.500
<b>Time Since Vaccination</b>	18	Wilcoxon Mann-Whitney U	1.27	0.0026	0.204
<b>Prior Infection</b>	0	Wilcoxon Mann-Whitney U	0.53	0.0026	0.595
<b>Prior Infection</b>	1	Wilcoxon Mann-Whitney U	-0.93	0.0026	0.352
<b>Prior Infection</b>	2	Wilcoxon Mann-Whitney U	-0.51	0.0026	0.613
<b>Prior Infection</b>	3	Wilcoxon Mann-Whitney U	-0.19	0.0026	0.849
<b>Prior Infection</b>	4	Wilcoxon Mann-Whitney U	-0.57	0.0026	0.569
<b>Prior Infection</b>	5	Wilcoxon Mann-Whitney U	-0.53	0.0026	0.594
<b>Prior Infection</b>	6	Wilcoxon Mann-Whitney U	-0.57	0.0026	0.569
<b>Prior Infection</b>	7	Wilcoxon Mann-Whitney U	-0.31	0.0026	0.760
<b>Prior Infection</b>	8	Wilcoxon Mann-Whitney U	-2.11	0.0026	0.035
<b>Prior Infection</b>	9	Wilcoxon Mann-Whitney U	-0.23	0.0026	0.819
<b>Prior Infection</b>	10	Wilcoxon Mann-Whitney U	-1.64	0.0026	0.101
<b>Prior Infection</b>	18	Wilcoxon Mann-Whitney U	-0.42	0.0026	0.676

9

10

11 **Supplementary Figure 1. Proportion of participants with specimens collected by day since onset**  
 12 **among fully vaccinated and not fully vaccinated participants.**




13

14 Bar heights indicate the proportion of participants in each group from whom a specimen was collected  
 15 on a given day since onset. Onset was determined to be either a) date of first onset of self-reported  
 16 symptom(s) meeting the case definition of COVID-19 or b) date of first positive diagnostic SARS-CoV-2  
 17 test, whichever occurred first. Not fully vaccinated participants include 2 participants who received only  
 18 the first dose of a two-dose COVID-19 vaccine series. Data labels indicate the total number of specimens  
 19 provided by participants from each group on each day.

20

21

22 **Supplementary Figure 2. Proportion of specimens for which a viral culture result is available among**  
 23 **fully vaccinated and not fully vaccinated participants.**




24

25 Bar heights indicate the proportion of specimens in each group for which a viral culture result is  
 26 available on a given day since onset. Specimens for which an accompanying RT-PCR result was negative,  
 27 or positive with a cycle threshold greater than 35, were presumed to have negative viral culture results  
 28 and are included here as having a culture result available. Onset was determined to be either a) date of  
 29 first onset of self-reported symptom(s) meeting the case definition of COVID-19 or b) date of first  
 30 positive diagnostic SARS-CoV-2 test, whichever occurred first. Not fully vaccinated participants include 2  
 31 participants who received only the first dose of a two-dose COVID-19 vaccine series. Data labels indicate  
 32 the total number of specimens provided by participants from each group on each day.

33

34

35 **Supplementary Figure 3 SARS-CoV-2 Cycle threshold and viral culture test results among fully**  
36 **vaccinated and not fully vaccinated participants among specimens with positive RT-PCR results.**



37

38 Points illustrate cycle threshold (Ct) values and culture results by specimens collected on a given day  
39 since onset. Panel A depicts specimens collected from fully vaccinated participants. Panel B depicts  
40 specimens collected from participants who were not fully vaccinated. Specimens with a positive culture  
41 result are depicted as closed circles; those with negative culture results are depicted as X's. Specimens  
42 with a positive RT-PCR result and Ct value greater than 35 but for which no viral culture was performed  
43 were presumed to have a negative viral culture result and are depicted as open circles. Specimens with a

44 negative RT-PCR result and thus no Ct value are not depicted here (but are included in all other analyses  
45 as having presumptive negative cultures). X-axis values are jittered to distinguish overlapping points.  
46 Onset was determined to be either a) date of first onset of self-reported symptom(s) meeting the case  
47 definition of COVID-19 or b) date of first positive diagnostic SARS-CoV-2 test, whichever occurred first.  
48 Not fully vaccinated participants include 2 participants who received only the first dose of a two-dose  
49 COVID-19 vaccine series.

50

51